HAVE ANY QUESTIONS? CLICK HERE
BIOMATLANTE joins the AMS Group
- Biomatlante News
Biomatlante is very pleased to announce the acquisition of 100% of its shares by Advanced Medical Solutions Group plc (London Alternative Investment Market: AMS).
The acquisition will strengthen AMS’s product portfolio, R&D pipeline, and market access. It provides the Group with a range of revenue-generating surgical products and an R&D pipeline of complementary biosurgical technologies and offers significant growth potential in additional surgical markets estimated to be worth $0.5 billion.
Biomatlante platform technologies will broaden the Group’s biosurgical technology offering while also offering multiple synergies across the sales, marketing, regulatory, operational divisions and R&D.
Commenting this acquisition, Chantal Gobin-Daculsi, Co-founder and President of Biomatlante said: "This is an important strategic step for Biomatlante and we are excited to become part of the AMS group. AMS is a high-quality global Company with the scale, expertise and track record of realising the value of scientific innovation and rapidly growing the sales of marketed products. As now part of the AMS family, the know-how of our team can be fully realised to pursue Biomatlante's continued growth in innovative bone regenerative technologies.”
Julien Dert, CEO of Biomatlante, added: “We are very pleased that Biomatlante has found a strong partner like AMS to pursue its development. All Biomatlante team, including its Co-founder Dr Guy Daculsi who will continue as our Scientific Advisor, is very enthusiastic and ready to drive the synthetic bone graft market forward.”
Commenting on the acquisition, Chris Meredith, CEO of AMS, said: “This acquisition is in line with our strategy to acquire technologies that are complementary to our surgical portfolio and allow us to leverage our global routes to market. The acquisition grants AMS access to multiple new markets, including the synthetic bone substitutes market which is estimated at $0.5 billion. We are excited to welcome the Biomatlante team to AMS and look forward to working together with them to accelerate the commercial success internationally and to continue to develop the Biomatlante technology in a wide range of potential applications and indications.”